Robots Hand the Blood Draw Needle to Algorithms: FDA Clears Autonomous Blood Collection Device for the First Time

Blood collection may seem routine, but it relies heavily on skilled personnel and often becomes a source of patient anxiety and healthcare workflow bottlenecks when veins are difficult to locate. The U.S. Food and Drug Administration (FDA) has now authorized Vitestro’s Aletta for marketing through the De Novo pathway, making it the first standalone robotic device in the United States capable of completing blood collection without manual human intervention.

Aletta first guides the patient in positioning their arm, then uses near-infrared light and Doppler ultrasound to locate a suitable vein and determine whether a blood vessel is an artery. If it cannot find an appropriate site, the system will not insert the needle. Once a target is confirmed, the device can automatically apply a tourniquet, disinfect the skin, insert and dispose of the needle, change blood collection tubes, and finally apply a dressing.

This authorization does not mean the robot can practice independently. Aletta can currently be used only in adult outpatient settings. Each blood draw must be initiated by a person trained in phlebotomy, who must remain on site to handle abnormalities. One phlebotomist may supervise no more than three devices at the same time and must still verify the order of the blood collection tubes and whether the blood volume is sufficient. The device is positioned more as a way to augment professional staff than to replace phlebotomists entirely.

The FDA said the clinical data submitted for review covered adults with different health conditions and skin tones, as well as those who self-reported having veins that were more difficult to access. When the device determined that needle insertion was possible and actually attempted venipuncture, its successful blood collection rate was comparable to or higher than that of trained personnel; device-related adverse events were rare and mild. However, the FDA announcement did not disclose the number of participants or the exact success rate, nor did it state how many procedures were abandoned because no suitable vein could be found. This comparison therefore cannot be interpreted to mean that the robot outperforms humans for everyone who presents for a blood draw.

To reduce puncture risks, the system continuously applies disinfectant during ultrasound scanning. If the patient moves too much, the needle can automatically disengage and stop the blood draw. Other sensors can also pause the procedure and notify the supervisor when an unsafe condition is detected. The device must still be cleaned by trained personnel after each patient, showing that automation has not eliminated responsibility for infection control and on-site response.

De Novo authorization applies to novel medical devices that lack an existing comparable product but are considered to pose low to moderate risk. The FDA also established special control requirements for this category of devices, including labeling, performance, and clinical testing requirements, potentially creating a new review pathway that similar products may follow in the future. Whether Aletta can truly shorten waiting times, improve the blood collection experience for patients with difficult veins, and maintain safety and efficiency during high-volume routine use remains to be answered by real-world post-market deployment data.